GlobeNewswire by notified

Inventiva announces the schedule of publication and presentation of its 2023 Full-Year Financial Results

Share

Daix (France), Long Island City (New York, United States), March 22, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), also known as non-alcoholic steatohepatitis (NASH), and other diseases with significant unmet medical needs, today announced that its management team will host a webcast to present the Company’s 2023 full-year financial results on Thursday, March 28, 2024.

Inventiva’s 2023 full-year financial results will be published on Wednesday, March 27, 2024 at 4:00 pm (New York), 9:00 pm (Paris).

Frédéric Cren, Chairman, CEO and cofounder of Inventiva, Pierre Broqua, Chief Scientific Officer and cofounder of Inventiva, and Jean Volatier, Chief Financial Officer of Inventiva, will hold a conference call in English, followed by a Q&A session, on Thursday, March 28, 2024, at8:00 am (New York), 1:00 pm (Paris).

The conference call and the slides of the presentation will be webcast live at: https://edge.media-server.com/mmc/p/eh78kegs and also available on Inventiva’s website in the “Investors – Financial results” section.

In order to receive the conference access information necessary to join the conference call, it is required to register in advance using the following link: https://register.vevent.com/register/BIca56dabf4edf46ecaaca0e735626f044. Participants will need to use the conference access information provided in the e-mail received at the point of registering (dial-in number and access code).

A replay of the conference call and the presentation will be available after the event at: http://inventivapharma.com/investors/financial-results-presentations/.



About Inventiva

Inventiva is a clinical-stage biopharmaceutical company focused on the research and development of oral small molecule therapies for the treatment of patients with MASH/NASH, and other diseases with significant unmet medical need. The Company benefits from a strong expertise and experience in the domain of compounds targeting nuclear receptors, transcription factors and epigenetic modulation. Inventiva is currently advancing one clinical candidate, has a pipeline of two preclinical programs and continues to explore other development opportunities to add to its pipeline.

Inventiva’s lead product candidate, lanifibranor, is currently in a pivotal Phase III clinical trial, NATiV3, for the treatment of adult patients with MASH/NASH, a common and progressive chronic liver disease for which there are currently no approved therapies.

Inventiva’s pipeline also includes odiparcil, a drug candidate for the treatment of adult MPS VI patients. As part of Inventiva’s decision to focus clinical efforts on the development of lanifibranor, it suspended its clinical efforts relating to odiparcil and is reviewing available options with respect to its potential further development. Inventiva is also in the process of selecting a candidate for its Hippo signaling pathway program.

The Company has a scientific team of approximately 90 people with deep expertise in the fields of biology, medicinal and computational chemistry, pharmacokinetics and pharmacology, and clinical development. It owns an extensive library of approximately 240,000 pharmacologically relevant molecules, approximately 60% of which are proprietary, as well as a wholly-owned research and development facility.

Inventiva is a public company listed on compartment B of the regulated market of Euronext Paris (ticker: IVA, ISIN: FR0013233012) and on the Nasdaq Global Market in the United States (ticker: IVA). www.inventivapharma.com

Contacts

Inventiva

Pascaline Clerc
EVP, Strategy and Corporate Affairs
media@inventivapharma.com
   +1 202 499 8937
Brunswick Group
Tristan Roquet Montegon /
Aude Lepreux /
Julia Cailleteau
Media relations
inventiva@brunswickgroup.com

   +33 1 53 96 83 83
Westwicke, an ICR Company
Patricia L. Bank
Investor relations
patti.bank@westwicke.com

         +1 415 513-1284

Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

ROCKWOOL A/S – transactions in connection with share buy-back programme17.4.2024 10:15:43 CEST | Press release

Company announcement for ROCKWOOL A/S Release no. 18 – 2024 to Nasdaq Copenhagen 17 April 2024 ROCKWOOL A/S – transactions in connection with share buy-back programme As mentioned in announcement no. 02/2024, ROCKWOOL A/S has initiated a share buy-back programme which will run from 8 February 2024 until 7 February 2025. During this period, the Company will buy own shares for up to a maximum of 160 MEUR. The programme is implemented in accordance with EU Commission Regulation No 596/2014 of 16 April 2014 and EU Commission Delegated Regulation No 2016/1052 of 8 March 2016, which together constitute the “Safe Harbour” regulation. The following transactions have been executed during the period 10 – 16 April 2024: DateNumber of B sharesAverage purchase price B shares (DKK)Aggregate amount, B shares (DKK)[Accumulated, last announcement]113,300248,494,39810 April 20241,0002,284.202,284,20011 April 20245,0002,250.3411,251,70012 April 20245,0002,244.6511,223,25015 April 20244,0002,241.128,964,4

ROCKWOOL A/S – transaktioner i henhold til aktietilbagekøbsprogram17.4.2024 10:15:43 CEST | pressemeddelelse

Selskabsmeddelelse for ROCKWOOL A/S Meddelelse nr. 18 – 2024 til Nasdaq Copenhagen 17. april 2024 ROCKWOOL A/S – transaktioner i henhold til aktietilbagekøbsprogram Som meddelt i selskabsmeddelelse nr. 02/2024 har ROCKWOOL A/S iværksat et aktietilbagekøbsprogram, som løber i perioden fra og med 8. februar 2024 og til og med den 7. februar 2025. I denne periode vil Selskabet købe egne aktier for op til maksimalt 160 mio. euro. Tilbagekøbsprogrammet gennemføres i henhold til EU-Kommissionens forordning nr. 596/2014 af 16. april 2014 og EU-Kommissionens delegerede forordning nr. 2016/1052 af 8. marts 2016, der tilsammen udgør ”Safe harbour” reguleringen. I perioden 10. – 16. april 2024 er foretaget følgende køb: DatoAntal B-aktierGennemsnitlig købspris B-aktier (DKK)Samlet beløb B-aktier (DKK)[I alt, seneste meddelelse]113.300248.494.39810. april 20241.0002.284,202.284.20011. april 20245.0002.250,3411.251.70012. april 20245.0002.244,6511.223.25015. april 20244.0002.241,128.964.48016. apri

Equinor ASA: Buy-back of shares to share programmes for employees17.4.2024 10:14:15 CEST | Press release

Please see below information about transactions made under the buy-back programme for Equinor ASA (OSE:EQNR, NYSE:EQNR) for shares to be used in the share-based incentive programmes for employees and management. Date on which the buy-back programme was announced: 7 February 2024. The duration of the buy-back programme: 15 February 2024 to 15 January 2025. Size of the buy-back programme: The total purchase amount under the programme is NOK 1,156,000,000 and the maximum shares to be acquired is 16,800,000 shares, of which up to 7,400,000 shares can be acquired in the period from 15 February 2024 to 15 May 2024, and up to 9,400,000 shares can be acquired in the period from 16 May 2024 to 15 January 2025. On 15 April 2024, Equinor ASA has purchased a total of 455,019 own shares at the Oslo Stock Exchange at an average price of NOK 305.4815 per share. Aggregated overview of transactions per day: DateAggregated volume (number of shares)Weighted average share price (NOK)Total transaction valu

HiddenA line styled icon from Orion Icon Library.Eye